WASHINGTON (Reuters) -U.S. regulators asked a federal judge on Friday to hold Martin Shkreli in contempt for allegedly impeding its efforts to determine whether he flouted a ban...
By Davit Kirakosyan DA Davidson lowered the price target on Accolade Inc (NASDAQ:ACCD) to $14.00 from $16.00 while maintaining a Buy rating. Shares surged more than 23% today...
Canopy Growth (NYSE:CGC) Corp CGC is scheduled to report fourth quarter and fiscal year 2020 ended Mar 31, results on May 29, before market open.In the third quarter of fiscal...
Investors in Retrophin, Inc. (NASDAQ:RTRX) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2020 $7.50 Put had...
The Zacks Medical-Biomedical and Genetics industry is up 8.6% this year so far compared with the S&P 500’s increase of 26.1%.The industry includes large as well as small...
Travere Therapeutics, Inc. is a biopharmaceutical company. It is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.